Cancer Archives

News and Trends 28 Nov 2022

Localizing BRCA gene mutations to better treat ovarian cancer

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […]

November 28, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

STORM Therapeutics doses first patient with drug targeting solid tumors

STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Nov 2022

XtalPi and CK Life Sciences partner on tumor vaccine R&D

XtalPi has entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a novel artificial intelligence (AI) tumor vaccine R&D platform. This will improve the discovery and design capabilities of tumor vaccines and accelerate development of more vaccine types. According to public information, […]

November 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

AI works on artificial DNA for future drug development

With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs […]

November 24, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

BC Platforms partners on AI-driven EU cancer data project

BC Platforms (BCP), a provider of healthcare data management and analytics, has been chosen as a key partner in a European Commission (EC) project. Under the EC’s Horizon Europe program, Helsinki University Hospital (HUS), has been awarded a contract to lead a €7 million ($7.2 million) consortium project termed ONCOVALUE. BCP will work with HUS […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […]

November 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Nov 2022

Achilles Therapeutics receives US patent for immunotherapies

A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine, antibody and autologous T cell therapy approaches, targeting clonal neoantigens identified using the Achilles Clonality Engine (ACE). ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS bioinformatics platform. Clonal […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Nov 2022

CatalYm raises €50M to boost solid tumors trial

CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

FogPharma raises $178M to target cancer

U.S biotech company FogPharma has announced a $178 million series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, […]

November 21, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

FMRP – the protein behind immunotherapy resistance

Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […]

November 21, 2022 - 6 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Localizing BRCA gene mutations to better treat ovarian cancer

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

STORM Therapeutics doses first patient with drug targeting solid tumors

XtalPi and CK Life Sciences partner on tumor vaccine R&D

AI works on artificial DNA for future drug development

BC Platforms partners on AI-driven EU cancer data project

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

Achilles Therapeutics receives US patent for immunotherapies

CatalYm raises €50M to boost solid tumors trial

FogPharma raises $178M to target cancer

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

FMRP – the protein behind immunotherapy resistance

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!